# The Safety & Efficacy of Imatinib for the Treatment of SARS-COV-2 Induced Pneumonia

> **NCT04422678** · PHASE3 · UNKNOWN · sponsor: **Alexandria University** · enrollment: 30 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Imatinib Mesylate
- **DRUG:** Standard of Care

## Key facts

- **NCT ID:** NCT04422678
- **Lead sponsor:** Alexandria University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06
- **Primary completion:** 2020-09
- **Final completion:** 2020-10
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2020-06-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04422678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04422678, "The Safety & Efficacy of Imatinib for the Treatment of SARS-COV-2 Induced Pneumonia". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04422678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*